शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans

This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →

BSEMercury Laboratories Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 5 Nov, 2026 · 11:21 IST

Standalone September quarter profit after tax falls to Rs 67.31 lakh

EBITDA margin compressionResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction

Awaiting price reaction for this filing.

AI summary

Standalone September 2026 quarter revenue was Rs 1,900.86 lakh, up 2.4 percent from Rs 1,855.74 lakh, and profit after tax fell 65.6 percent to Rs 67.31 lakh from Rs 195.51 lakh a year earlier. Standalone half-year profit after tax was Rs 97.09 lakh versus Rs 261.09 lakh, while operating cash flow remained positive at Rs 89.11 lakh. The results were unaudited and received a limited review.

Likely market impact

Profit fell about 66 percent and the operating margin narrowed, which may pressure the stock despite positive cash flow and low borrowings.

By the numbersStandalone · Q2 FY27 vs Q2 FY26
Q2 FY27Q2 FY26Change
Revenue₹19.01 Cr₹19.01 Cr+0.0%
Operating profit₹0.54 Cr₹1.13 Cr−52.5%
Profit after tax₹0.67 Cr₹1.64 Cr−59.0%
EBITDA margin7.6%11.2%−3.6 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.